

A TALE OF TWO AUDIENCES:

OPTIMISING YIELD FROM EARLY ADVICE CONSULTATION WITH HTA AND REGULATORY ORGANISATIONS

WORKSHOP: ISPOR EUROPE 2014

Amsterdam, Netherlands NOVEMBER 12, 2014

CONFIDENTIAL

NEW YORK CITY SAN FRANCISCO LONDON SHANGHAI

Our panel will include:

CYRUS A.CHOWDHURY, MS

CEO & MANAGING DIRECTOR CBPARTNERS

RACHEL BECKERMAN, PHD

PRINCIPAL, VALUE DEMONSTRATION CBPARTNERS

MARIJE VAN WEELDEN, MBA, MD, MSC DIRECTOR, MARKET ACCESS AND PRICING EUROPE

FERRING

MATTHIEU R. CUCHE, PharmD, MBA DIRECTOR HCE & REIMBURSEMENT COVIDIEN AG







2

The objective of this workshop is to provide an overview of early models and how they fit into today's market access planning efforts.


OVERALL WORKSHOP GOAL

To provide an overview of early models and how they fit into today's market access planning efforts

WORKSHOP OBJECTIVES


- Explain models for early advice
- Explore case studies of recent products that have sought, achieved, and incorporated early advice
- ✓ Understand the associated opportunities and challenges of pursuing an early-advice approach






The past few years have clearly demonstrated that key elements of clinical trial design have major and unique effects on both regulatory and reimbursement decisions.

Trial designs determined in 2010 and earlier are now achieving market authorisation globally, with access in the EM to follow in the coming years.






Pivotal trial design decisions must be made far in advance of traditional access engagement with HTA authorities, commonly leading to evidence misalignment.

Agenda

13:45 – 13:55 Introductions & Objectives	13:55 - 14:07 Models for Early Advice	14:07 – 14:19 Case Studies	<mark>14:19 – 14:31</mark> The MFG Perspective	14:31 – 14:45 Wrap-Up and Q&A	
 Introduction Meeting Objectives Overview of the Issues 	 The Four Early Advice Models Similarities and Differences 	 Publically Available Examples Overview Key Findings 	 Opportunities Challenges Recommendations for Engagement 	 Summary Learnings / Questions 	



Four identified main models for HTA advice




BPARTNERS

The key characteristics of HTA advice

	GER	SWE	UK	NLD	Pan-EU	Regulatory / EL HTA
	G-BA / IQWiG	TLV	NICE	ZIN	EUnetHTA	EMA / HTAs
CONJOINT REGULATORY ADVICE	Mandatory	Mandatory	Possible	Not Possible	Not Possible	Possible
CONSULTATION TIMELINES (MONTHS)	2	2	4	2	4.5	4.5
FEES (EUROS)	10,000 – 20,000	5,000	20,000 - 60,000	0	0	20,000 - 60,000
ουτρυτ	Meeting minutes	Meeting minutes	Report	Report	Meeting minutes	Variable based on HTA body
ABILITY TO ASSESS HEALTH ECONOMICS	N/A	Yes	Yes	Yes	Yes	Variable
LANGUAGE OF MEETING	German	English	English	English	English	English
LENGTH OF MEETING	1 to 2 hours	1.5 hours	~3 hours	Unknown	3 hours	~4 hours
NUMBER OF 'COMPANY ATTENDEES' ALLOWED	4 to 6	No limit	Variable	1 to 2	<10	Variable
INVOLVEMENT OF EXTERNAL EXPERTS POSSIBLE	No	No	Yes	No	No	No
PARTNERS						

EMA – HTA Advice: attendance by HTA Agency




BPARTNERS


Source Leeza Osipenko - 9 October, representing NICE at PharmAccess Leaders Forum , Berlin


10

As an example: Flowchart Scientific advice process with NICE (https://www.nice.org.uk)









Tapestry Networks has held six pilots for the multi-HTA approach; key findings

BPARTNERS

Source: http://www.tapestrynetworks.com/initiatives/healthcare/upload/Pilots-of-multi-stakeholder-consultations-in-drug-development-6-June-2012.pdf

14


GreenPark Collaborative has run an initial pilot exploring the impact of early advice in the Alzheimer's space.

0	STATUS: 1 PILOT C	IRY HTA PARALLEL REGULATORY + SINGLE-COUNTRY HTA			
TIMING: October 2011 - April 2013 THERAPEUTIC AREA: Alzheimer's Disease PARTICIPANTS: REGULATOR PAYER / HTA		 KEY FINDINGS International pilot exploring the feasibility of providing early HTA advice; 11 companies with AD products in various stages of clinical development assisted in the development of the guidelines (EGD) by identifying questions about clinical study design that would be most useful to understand from the HTA / coverage perspective. The pilot demonstrated that such a multi-faceted consultation process is feasible However, key learnings / areas of improvement from the pilot include: 			
		 However, key learnings / areas of improvement from the pilot inclu Focus first on changes to trials that do not add significant co or time Highlight comparisons with related guidance Choose topics that offer prominent opportunities for guidanc Increase patient and expert involvement Provide additional opportunities for in-person engagement 			
Source: GPC Pike	ot Evaluation Report – Apri	12013 15			


EUNetHTA's Joint Action 2 WP7 workstream has completed 10 early dialogue pilots.

SINGLE COL eunethta SINGLE COL MULTI-COUT TIMING: 2012 - 2015 THERAPEUTIC AREA: T2DM, Breast Cancer, Melanoma, NSCLC, Alzheimer's Disease, Antibiotics PARTICIPANTS: REGULATOR N/A N/A N/A SINGLE COL MULTI-COUT MULTI-COUT	KEY FINDINGS The process is coordinated and hosted by HAS, France; other HTA
BPARTNERS	16

The Shaping Early European Dialogues (SEED) consortium is leading a set of 10 early advice pilots as a follow-on to EUnetHTA's efforts.



PARTNERS



EFPIA has performed a survey to elicit MFG experience with the early advice process.

NVS has published their select experiences with early dialogue, as has the Italian Medicines Agency (AIFA).

NVS AND AIFA EARLY DIALOGUE EXPERIENCE KEY FINDINGS



NVS EXPERIENCE

- Relatively few differences between demands of regulators and payers
- Only one payer agency was able to provide formal written feedback
- ✓ Company perceived formal and informal advice given to be helpful and worthwhile



AIFA EXPERIENCE

- ✓ Over 3 years, 21 early dialogues were performed across single-HTA, multi-HTA, and parallel regulatory-HTA models
- ✓ CNS and oncology were main TAs for which advice was sought
- Most EDs were performed during Phase II or III of development
- ✓ A lower concordance between AIFA and the MFGs existed related to target population, subgroup selection, choice of comparators, and resource utilisation data collection








Case study

Regulatory scientific advice not aligned with HTA expectations




22

Rationalising R&D Spend



Enhanced internal alignment

- Historically regulatory approval was only internal focus
- Pricing, reimbursement and market access were an add-on Had to work from regulatory focused trials
- Early HTA scientific advice allows for constructive discussions and aligned expectations






24

When to conduct Early Scientific Advice?

Analysis of requests at NICE:

- Before phase III: 72 (67%)
- During phase III (pivotal trials started): 19 (18%)
- Other (prior to) phase II and after phase III: 16 (15%)



Engaging in the early advice process has clear advantages...

- Opportunity for internal engagement and alignment of expectations
- HTA feedback before final data package is available:
 - Obtain payer perspective before clinical trials even start
 - Maximize usefulness of data collected
 - Consider pros and cons of different trial options
 - Obtain ideas on alternative strategies to be developed
 - Integrate CE in early decision making
- <u>Parallel</u> advice: members from regulatory and HTA bodies in one meeting
- NICE scientific advice: patient's engagement



26

...although disadvantages and uncertainties exist too

- Preparation can be resource-intensive
- Advice is non-binding and not guaranteed of P&R success
- Output of advice is not always clear or straightforward
- Many models exist; early dialogue does not have a clear 'owner'
- No public examples of facilitated P&R based on the early advice process
- Recommendations regulatory and HTA may differ
 - Different SoC between countries

- Off-label may be accepted as comparator in some countries, not in others
- Competitive environment might change between consultation and reimbursement submission
- Parallel advice: not all parties can be heard



The range of topics discussed can be very broad (slide 1 of 2)

Trial-related topics for early advice

- Study population
 - Including stats: subgroups and stratification
- Position of intervention in treatment pathway
- Comparator(s)
- Design of the trial (duration, dosing)
- Acceptability of endpoints / surrogate endpoints
- PROs generic and disease specific



28

The range of topics discussed can be very broad (slide 2 of 2)

Economics-related topics for early advice

- Plans for model to be used
- Sources of data
 - Observational studies
 - Analyses
- Utility value definition
- Resource utilisation collection



Which models are most helpful and why

It depends...

Parallel EMA – HTA Scientific advice has my preference

One meeting where regulatory and HTA bodies come together Goal to align and find (between HTAs) during the meeting Essential in era of increasing HTA requirements & cost containment



30

Which models are most helpful and why

It depends...

In case of a local development strategy: (series of) national advice

In-depth discussion with HTA body Advice is specifically targeted to later HTA submission in that market

Maybe a chance to "manage expectations" of HTA body







32

Summary

- Manufacturers face many challenges in obtaining reimbursement in the diverse European climate
- 4 models for early dialogues were presented
- Real-world experiences of early dialogues highlighted both the positive experiences as well as where there is room for improvement
- An overview of manufacturer's considerations for engagement in the early dialogue process





Questions?



34

For a copy of our slides please email us:

CYRUS A.CHOWDHURY, MS Cyrus.Chowdhury@cbpartners.com CEO & MANAGING DIRECTOR CBPARTNERS

RACHEL BECKERMAN, PHD Rachel.Beckerman@cbpartners.com PRINCIPAL, VALUE DEMONSTRATION CBPARTNERS

MARIJE VAN WEELDEN, MBA, MD, MSC Marije.vanWeelden@ferring.com DIRECTOR, MARKET ACCESS AND PRICING EUROPE FERRING

> MATTHIEU R. CUCHE, PharmD, MBA Matthieu.Cuche@covidien.com DIRECTOR HCE & REIMBURSEMENT COVIDIEN AG

